Dr John M Hillyard, MD | |
1899 E Mystic Grove Cv, Cottonwood Heights, UT 84093-5509 | |
(801) 935-1983 | |
(385) 255-9888 |
Full Name | Dr John M Hillyard |
---|---|
Gender | Male |
Speciality | Orthopaedic Surgery - Adult Reconstructive Orthopaedic Surgery |
Location | 1899 E Mystic Grove Cv, Cottonwood Heights, Utah |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1669416129 | NPI | - | NPPES |
039507101 | Medicaid | TX |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207XS0114X | Orthopaedic Surgery - Adult Reconstructive Orthopaedic Surgery | 168816-1205 (Utah) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr John M Hillyard, MD 1899 E Mystic Grove Cv, Cottonwood Heights, UT 84093-5509 Ph: (801) 935-1983 | Dr John M Hillyard, MD 1899 E Mystic Grove Cv, Cottonwood Heights, UT 84093-5509 Ph: (801) 935-1983 |
News Archive
As we grow older, our brains undergo a major reorganisation reducing the connections in the brain. Studying people up to the age of 40, scientists led by Dr Marcus Kaiser and Ms Sol Lim at Newcastle University found that while overall connections in the brain get streamlined, long-distance connections that are crucial for integrating information are preserved.
Health Robotics announced that it launched its post-McKesson era with record-breaking American results in 2Q2011, including 4 new robot installs completed, 18 new installations under contract, and 4 new enterprise agreements with Sandoz Canada, Grifols, Americorp Financial, and Donawa Consulting that continued the expense-intensive process to replace McKesson Automation, while substantially expanding the service scope of Health Robotics Canada Inc. (HRCI).
By the time they're two, most children have had respiratory syncytial virus and suffered symptoms no worse than a bad cold. But for some children, especially premature babies and those with underlying health conditions, RSV can lead to pneumonia and bronchitis - which can require hospitalization and have long-term consequences.
Cipher Pharmaceuticals Inc. today announced that it reached a cumulative sales milestone for Lipofen, the Company's fenofibrate product. Achieving this target triggers a US$1.0 million milestone payment from Kowa Pharmaceuticals America Inc., Cipher's U.S. marketing and distribution partner, which will be reflected in Cipher's revenue for the second quarter of fiscal 2010.
› Verified 3 days ago